Seagen and LAVA Therapeutics, participated by Ysios, Announce Exclusive Worldwide License Agreement to Advance LAVA-1223

Entorno y otros, Venture Capital

27/09/2022 Nota de prensa SEAGEN AND LAVA THERAPEUTICS ANNOUNCE EXCLUSIVE WORLDWIDE LICENSE AGREEMENT TO ADVANCE LAVA-1223, A PRECLINICAL GAMMA DELTA BISPECIFIC T CELL ENGAGER FOR EGFR-EXPRESSING SOLID TUMORS Seagen to Develop and Commercialize LAVA-1223, a Bispecific T Cell Engager Designed to Target and Activate Vγ9Vδ2 (Gamma Delta) T Cells in the Presence of EGFR-Expressing Solid…

LAVA Therapeutics, participated by Ysios Capital, announces pricing of Initial Public Offering

Desinversión, Venture Capital

26/03/2021 Press release LAVA THERAPEUTICS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING.           UTRECHT, The Netherlands and PHILADELPHIA, March 24, 2021 (GLOBE NEWSWIRE) — LAVA Therapeutics B.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy, today announced the pricing of…

Ysios Capital anuncia la salida a bolsa en el NASDAQ de su compañía participada LAVA Therapeutics

Desinversión, Venture Capital

26/03/2021 Nota de prensa YSIOS CAPITAL ANUNCIA LA SALIDA A BOLSA EN EL NASDAQ DE SU COMPAÑÍA PARTICIPADA LAVA THERAPEUTICS.           − LAVA Therapeutics (Utrecht, Países Bajos), es una compañía biotecnológica pionera en el desarrollo de anticuerpos biespecíficos para potenciar el papel de las células T gamma-delta en terapias contra el…

Lava Therapeutics completes $83M Series C round lead by Novo Holdings and Sanofi Ventures, and also followed up by Ysios, Redmile Biopharma, BB Pureos and current shareholders

Inversión, Venture Capital

18/09/2020 Press release LAVA THERAPEUTICS ANNOUNCES $83 MILLION SERIES C FINANCING TO ADVANCE NOVEL IMMUNO-ONCOLOGY PROGRAMS.     Funding to support advancement of powerful bispecific gamma-delta T cell engager programs for the treatment of a broad range of cancers New investors include Novo Holdings, Sanofi Ventures, Redmile, Ysios and BB Pureos Utrecht, The Netherlands and…

Lava Therapeutics cierra una ronda de €71M liderada por Novo Holdings y Sanofi Ventures. Acuden también Ysios Capital, Redmile Biopharma, BB Pureos Bioventures e inversores existentes

Inversión, Venture Capital

18/09/2020 Nota de prensa YSIOS CAPITAL INVIERTE EN LAVA THERAPEUTICS PARTICIPANDO EN UNA RONDA DE €71 MILLONES.   − Lava Therapeutics (Utrecht, Países Bajos), es una compañía biotecnológica pionera en el desarrollo de anticuerpos biespecíficos para potenciar el papel de las células T gamma-delta en terapias contra el cáncer. − Ysios Capital ha participado en…